S&P 500   3,096.63 (+0.08%)
DOW   27,781.96 (-0.01%)
QQQ   201.43 (-0.08%)
AAPL   262.64 (-0.69%)
FB   193.15 (-0.02%)
MSFT   148.06 (+0.51%)
GOOGL   1,309.15 (+1.00%)
AMZN   1,754.60 (+0.08%)
CGC   15.84 (-14.38%)
NVDA   209.79 (+0.58%)
MU   46.80 (+1.08%)
BABA   182.80 (+0.18%)
GE   11.29 (+0.00%)
TSLA   349.35 (+0.94%)
T   38.95 (-0.54%)
AMD   38.35 (+2.21%)
F   8.79 (-0.23%)
ACB   3.29 (-7.32%)
PRI   130.20 (+1.24%)
NFLX   289.62 (+2.30%)
BAC   32.70 (-0.27%)
GILD   63.81 (+0.76%)
DIS   147.15 (-1.06%)
S&P 500   3,096.63 (+0.08%)
DOW   27,781.96 (-0.01%)
QQQ   201.43 (-0.08%)
AAPL   262.64 (-0.69%)
FB   193.15 (-0.02%)
MSFT   148.06 (+0.51%)
GOOGL   1,309.15 (+1.00%)
AMZN   1,754.60 (+0.08%)
CGC   15.84 (-14.38%)
NVDA   209.79 (+0.58%)
MU   46.80 (+1.08%)
BABA   182.80 (+0.18%)
GE   11.29 (+0.00%)
TSLA   349.35 (+0.94%)
T   38.95 (-0.54%)
AMD   38.35 (+2.21%)
F   8.79 (-0.23%)
ACB   3.29 (-7.32%)
PRI   130.20 (+1.24%)
NFLX   289.62 (+2.30%)
BAC   32.70 (-0.27%)
GILD   63.81 (+0.76%)
DIS   147.15 (-1.06%)
S&P 500   3,096.63 (+0.08%)
DOW   27,781.96 (-0.01%)
QQQ   201.43 (-0.08%)
AAPL   262.64 (-0.69%)
FB   193.15 (-0.02%)
MSFT   148.06 (+0.51%)
GOOGL   1,309.15 (+1.00%)
AMZN   1,754.60 (+0.08%)
CGC   15.84 (-14.38%)
NVDA   209.79 (+0.58%)
MU   46.80 (+1.08%)
BABA   182.80 (+0.18%)
GE   11.29 (+0.00%)
TSLA   349.35 (+0.94%)
T   38.95 (-0.54%)
AMD   38.35 (+2.21%)
F   8.79 (-0.23%)
ACB   3.29 (-7.32%)
PRI   130.20 (+1.24%)
NFLX   289.62 (+2.30%)
BAC   32.70 (-0.27%)
GILD   63.81 (+0.76%)
DIS   147.15 (-1.06%)
S&P 500   3,096.63 (+0.08%)
DOW   27,781.96 (-0.01%)
QQQ   201.43 (-0.08%)
AAPL   262.64 (-0.69%)
FB   193.15 (-0.02%)
MSFT   148.06 (+0.51%)
GOOGL   1,309.15 (+1.00%)
AMZN   1,754.60 (+0.08%)
CGC   15.84 (-14.38%)
NVDA   209.79 (+0.58%)
MU   46.80 (+1.08%)
BABA   182.80 (+0.18%)
GE   11.29 (+0.00%)
TSLA   349.35 (+0.94%)
T   38.95 (-0.54%)
AMD   38.35 (+2.21%)
F   8.79 (-0.23%)
ACB   3.29 (-7.32%)
PRI   130.20 (+1.24%)
NFLX   289.62 (+2.30%)
BAC   32.70 (-0.27%)
GILD   63.81 (+0.76%)
DIS   147.15 (-1.06%)
Log in

Pacira Biosciences Stock Price, Forecast & Analysis (NASDAQ:PCRX)

$42.58
-0.29 (-0.68 %)
(As of 11/14/2019 04:00 PM ET)
Today's Range
$42.26
Now: $42.58
$43.00
50-Day Range
$36.54
MA: $39.81
$44.65
52-Week Range
$34.64
Now: $42.58
$50.30
Volume349,700 shs
Average Volume626,656 shs
Market Capitalization$1.78 billion
P/E Ratio146.83
Dividend YieldN/A
Beta1.13
Pacira BioSciences, Inc provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure. It offers EXPAREL, a non-opioid medication administered at the time of surgery to control pain while reducing opioid requirements; and iovera system, a handheld cryoanalgesia device used to deliver controlled doses of cold temperature only to targeted nerves. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:PCRX
CUSIP69512710
Phone973-254-3560

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$337.28 million
Cash Flow$0.94 per share
Book Value$8.31 per share

Profitability

Net Income$-470,000.00

Miscellaneous

Employees518
Market Cap$1.78 billion
Next Earnings Date2/27/2020 (Estimated)
OptionableOptionable

Receive PCRX News and Ratings via Email

Sign-up to receive the latest news and ratings for PCRX and its competitors with MarketBeat's FREE daily newsletter.


Pacira Biosciences (NASDAQ:PCRX) Frequently Asked Questions

What is Pacira Biosciences' stock symbol?

Pacira Biosciences trades on the NASDAQ under the ticker symbol "PCRX."

How were Pacira Biosciences' earnings last quarter?

Pacira Biosciences Inc (NASDAQ:PCRX) posted its earnings results on Thursday, November, 7th. The company reported $0.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.13 by $0.35. The business had revenue of $104.69 million for the quarter, compared to analyst estimates of $104.88 million. Pacira Biosciences had a net margin of 0.55% and a return on equity of 10.19%. The company's revenue for the quarter was up 25.5% on a year-over-year basis. During the same period in the prior year, the company posted $0.31 EPS. View Pacira Biosciences' Earnings History.

When is Pacira Biosciences' next earnings date?

Pacira Biosciences is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Pacira Biosciences.

What price target have analysts set for PCRX?

11 Wall Street analysts have issued 12-month price objectives for Pacira Biosciences' shares. Their forecasts range from $38.00 to $85.00. On average, they expect Pacira Biosciences' stock price to reach $53.10 in the next twelve months. This suggests a possible upside of 24.7% from the stock's current price. View Analyst Price Targets for Pacira Biosciences.

What is the consensus analysts' recommendation for Pacira Biosciences?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pacira Biosciences in the last year. There are currently 1 sell rating, 4 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Pacira Biosciences.

What are Wall Street analysts saying about Pacira Biosciences stock?

Here are some recent quotes from research analysts about Pacira Biosciences stock:
  • 1. According to Zacks Investment Research, "Pacira changed its name to Pacira BioSciences following the acquisition of MyoScience in April 2019. Pacira’s top line mainly comprises contribution from its marketed drug Exparel. The company’s efforts to expand Exparel's label are encouraging. In April 2018, the FDA approved Exparel's label expansion to include administration via nerve block for prolonged regional analgesia. This is a positive for the company as it will further boost sales of Exparel. Pacira’s agreement with Nuance for the development/commercialization of Exparel in China is also an upside. Shares of the company have underperformed the industry year to date. The company remains heavily dependent on Exparel for growth, any setback for the drug will severely hurt the stock in the long run." (8/2/2019)
  • 2. Stifel Nicolaus analysts commented, "We are upgrading shares of PCRX to Hold as we believe the near-term competitive threat from HRTX’s HTX-011 will be less of a factor over the next 12 months and the recent strength in the stock indicates to us that the stock is fairly valued at these levels. While PCRX’s Exparel revenues came in a little shy of 1Q19 consensus, we believe the recent price increase on Exparel, the lack of a competitive entry from HRTX and the favorable reimbursement scheme in the ASC setting should allow PCRX to achieve its 2019 Exparel guidance, in our view. Our revised 2019 Exparel estimates are now at the midpoint of management’s guidance of ~$400-$410 million (vs. consensus of ~$403 million). Additionally, we incorporate PCRX’s recent acquisition, Iovera, into our model and raise our target price to $45 a share." (5/2/2019)

Has Pacira Biosciences been receiving favorable news coverage?

Media coverage about PCRX stock has trended somewhat negative recently, InfoTrie reports. The research group identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Pacira Biosciences earned a news sentiment score of -1.4 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Pacira Biosciences.

Are investors shorting Pacira Biosciences?

Pacira Biosciences saw a increase in short interest in the month of October. As of October 15th, there was short interest totalling 4,350,000 shares, an increase of 24.3% from the September 15th total of 3,500,000 shares. Based on an average daily trading volume, of 774,200 shares, the short-interest ratio is presently 5.6 days. Approximately 10.8% of the shares of the stock are short sold. View Pacira Biosciences' Current Options Chain.

Who are some of Pacira Biosciences' key competitors?

What other stocks do shareholders of Pacira Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pacira Biosciences investors own include Gilead Sciences (GILD), Celgene (CELG), ACADIA Pharmaceuticals (ACAD), Clovis Oncology (CLVS), Bausch Health Companies (BHC), Exelixis (EXEL), Micron Technology (MU), Incyte (INCY), Neurocrine Biosciences (NBIX) and GW Pharmaceuticals PLC- (GWPH).

Who are Pacira Biosciences' key executives?

Pacira Biosciences' management team includes the folowing people:
  • Mr. David M. Stack, Chairman & CEO (Age 69)
  • Mr. Charles A. Reinhart III, CPA, M.B.A., Chief Financial Officer (Age 58)
  • Ms. Kristen Williams, Chief Admin. Officer & Sec. (Age 45)
  • Dr. Richard Scranton M.D., MPH, Chief Medical Officer (Age 52)
  • Mr. Dennis McLoughlin, Chief Commercial Officer (Age 53)

Who are Pacira Biosciences' major shareholders?

Pacira Biosciences' stock is owned by many different of institutional and retail investors. Top institutional investors include Stephens Investment Management Group LLC (3.03%), Tamarack Advisers LP (1.86%), Rice Hall James & Associates LLC (1.03%), Peregrine Capital Management LLC (0.81%), DPM Capital LLC (0.47%) and Rhumbline Advisers (0.31%). Company insiders that own Pacira Biosciences stock include Andreas Wicki, Charles A Reinhart III, Charles Anthony Laranjeira, David M Stack, Gary W Pace, James B Jones, Kristen Marie Williams, Lauren Bullaro Riker, Mark A Kronenfeld, Paul J Hastings and Richard Scranton. View Institutional Ownership Trends for Pacira Biosciences.

Which institutional investors are selling Pacira Biosciences stock?

PCRX stock was sold by a variety of institutional investors in the last quarter, including Lisanti Capital Growth LLC, Russell Investments Group Ltd., Rice Hall James & Associates LLC, Legacy Capital Partners Inc., SignalPoint Asset Management LLC, Malaga Cove Capital LLC and Nisa Investment Advisors LLC. Company insiders that have sold Pacira Biosciences company stock in the last year include Andreas Wicki, Charles A Reinhart III, Charles Anthony Laranjeira, David M Stack, Kristen Marie Williams, Lauren Bullaro Riker, Paul J Hastings and Richard Scranton. View Insider Buying and Selling for Pacira Biosciences.

Which institutional investors are buying Pacira Biosciences stock?

PCRX stock was acquired by a variety of institutional investors in the last quarter, including DPM Capital LLC, Tamarack Advisers LP, Rhumbline Advisers, State of New Jersey Common Pension Fund D, Stephens Investment Management Group LLC, First Trust Advisors LP, Peregrine Capital Management LLC and California Public Employees Retirement System. Company insiders that have bought Pacira Biosciences stock in the last two years include Gary W Pace and Mark A Kronenfeld. View Insider Buying and Selling for Pacira Biosciences.

How do I buy shares of Pacira Biosciences?

Shares of PCRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Pacira Biosciences' stock price today?

One share of PCRX stock can currently be purchased for approximately $42.58.

How big of a company is Pacira Biosciences?

Pacira Biosciences has a market capitalization of $1.78 billion and generates $337.28 million in revenue each year. The company earns $-470,000.00 in net income (profit) each year or $0.29 on an earnings per share basis. Pacira Biosciences employs 518 workers across the globe.View Additional Information About Pacira Biosciences.

What is Pacira Biosciences' official website?

The official website for Pacira Biosciences is http://www.pacira.com/.

How can I contact Pacira Biosciences?

Pacira Biosciences' mailing address is 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054. The company can be reached via phone at 973-254-3560 or via email at [email protected]


MarketBeat Community Rating for Pacira Biosciences (NASDAQ PCRX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  684 (Vote Outperform)
Underperform Votes:  508 (Vote Underperform)
Total Votes:  1,192
MarketBeat's community ratings are surveys of what our community members think about Pacira Biosciences and other stocks. Vote "Outperform" if you believe PCRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PCRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/14/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel